← All trials
NCT04930744
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2021
- Primary completion
- Jul 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Jun 18, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MassachusettsLead sponsor
- University of MassachusettsOverall official - principal investigator
- University of MassachusettsReponsible party - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Aurum InstituteStudy chair
- Aurum InstituteCollaborator
- University of Cape TownCollaborator
- A*StarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.